Supernus Pharmaceuticals, Inc.
SUPN
$49.10
-$0.42-0.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.12M | 22.50M | -11.83M | 15.33M | 38.50M |
| Total Depreciation and Amortization | 24.81M | 21.36M | 20.38M | 18.85M | 20.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.85M | 3.19M | 8.14M | 15.36M | 2.81M |
| Change in Net Operating Assets | -49.20M | 11.49M | 13.91M | -5.13M | -7.89M |
| Cash from Operations | -61.66M | 58.54M | 30.60M | 44.41M | 53.52M |
| Capital Expenditure | -129.00K | -455.00K | -327.00K | -213.00K | -200.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -293.09M | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 341.93M | -30.15M | 37.64M | -12.43M | -76.81M |
| Cash from Investing | 48.71M | -30.61M | 37.32M | -12.64M | -77.01M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 23.74M | 3.28M | 2.04M | 6.88M | 3.46M |
| Repurchase of Common Stock | -811.00K | -46.00K | -3.34M | -987.00K | -387.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.86M | -2.30M | -20.10M | -- | -- |
| Cash from Financing | 21.07M | 935.00K | -21.40M | 5.89M | 3.08M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8.11M | 28.86M | 46.52M | 37.66M | -20.42M |